{"id":"W4389500584","doi":"10.1016/j.eururo.2023.11.016","title":"Corrigendum to “Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study” [Eur Urol 84(5) (2023) 449–454]","year":2023,"lang":"en","type":"erratum","venue":"European Urology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université Laval","funders":"","keywords":"Medicine; Axitinib; Sunitinib; Pembrolizumab; Renal cell carcinoma; Urology; Oncology; Internal medicine; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002800834,0.00200526,0.003333841,0.002234516,0.001777358,0.003091924,0.002806863,0.007918529,0.05853566],"category_scores_gemma":[0.02023004,0.001137539,0.003394784,0.001613626,0.0009413873,0.001259477,0.001053212,0.008594049,0.03682406],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.004589087,"about_ca_system_score_gemma":0.005368009,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.03327996,"about_ca_topic_score_gemma":0.05228658,"domain_scores_codex":[0.9974743,0.000405095,0.000403276,0.0003638792,0.001008442,0.0003451097],"domain_scores_gemma":[0.9906592,0.002702362,0.0007279115,0.0003692931,0.004536602,0.001004523],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00005441144,0.00001093892,0.00004261929,0.00005003933,0.00001427972,0.00008759959,0.000002574977,0.00001986845,0.00001676641,0.00005504899,0.9968533,0.002792561],"study_design_scores_gemma":[0.000399427,0.000108721,0.002218237,0.0002971008,0.0001452504,0.0003540047,0.00002161758,0.0002935672,0.0002130275,0.0005465994,0.9953597,0.00004264395],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"editorial","genre_gemma":"editorial","genre_scores_codex":[0.0001348926,0.002702171,0.000202141,0.09556106,0.8928214,0.00007212477,0.001959003,0.0002224279,0.006324817],"genre_scores_gemma":[0.004413722,0.008539943,0.001159438,0.2738104,0.4973468,0.0002359888,0.004257286,0.0003987216,0.2098377],"genre_candidate":"editorial","genre_consensus":"editorial","teacher_disagreement_score":0.05853566,"threshold_uncertainty_score":0.1958213,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05561973389941172,"score_gpt":0.3004993667631886,"score_spread":0.2448796328637768,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}